Infection-immunity liaison: Pathogen-driven autoimmune-mimicry (PDAIM)

Autoimmunity Reviews

Volumn 13, Issue 10, 2014, Pages 1064-1069

  Saeki, Yukihiko ^a   Ishihara, Katsuhiko ^b  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Autoimmune diseases; Autoimmunity; Autoreactive cells; Infectious agents

Indexed keywords

AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFECTION; INFECTION SENSITIVITY; INFLAMMATION; MOLECULAR MIMICRY; NONHUMAN; PATHOGEN DRIVEN AUTOIMMINE MIMICRY; PATHOGENESIS; REVIEW; ANIMAL; AUTOIMMUNE DISEASES; COMPLICATION; IMMUNOLOGY; MICROBIOLOGY;

AUTOANTIGEN;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; INFECTION;

EID: 84908146899     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.024     Document Type: Review

References (63)

1. Salvetti M., Ristori G., Bomprezzi R., Pozzilli P., Leslie R.D. Twins: mirrors of the immune system. Immunol Today 2000, 21:342-347.
2. Ercolini A.M., Miller S.D. The role of infections in autoimmune disease. Clin Exp Immunol 2008, 155:1-15.
3. Root-Bernstein R., Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep 2014, 14:407-413.
4. Amital H., Goroni M., Maya R., Meroni P.L., Ori B., Shoenfeld Y., et al. Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 2008, 26(1 Suppl. 48):S27-S32.
5. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
6. Rose N.R., Bona C. Defying criteria for autoimmune diseases (Witebsky's postulates revised). Immunol Today 1993, 14:426-430.
7. Suerbaum S., Michetti P. Helicobacter pylori infection. N Engl J Med 2002, 347:1175-1186.
8. Hasni S.A. Role of Helicobacter pylori infection in autoimmune diseases. Curr Opin Rheumatol 2012, 24:429-434.
9. Gasbarrini A., Franceschi F., Tartaglione R., Landolfi R., Pola P., Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998, 352:878.
10. Stasi R., Sarpatwari A., Segal J.B., Osborn J., Evagelista M.L., Cooper N., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systemic review. Blood 2009, 113:1231-1240.
11. He R., Reid D.M., Jones C.E., Shulman N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994, 83:1024-1032.
12. Nurden A.T. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995, 74:345-351.
13. Gorski J., Yassai M., Wu S., Maslanka K. T cell immunobiology of alloimmune thrombocytopenias. Arch Immunol Ther Exp (Warsz) 1998, 46:269-275.
14. Uhrynowska M., Maslanka K., Zupanska B. Neonatal thrombocytopenia: incidence, serological and clinical observations. Am J Perinatol 1997, 14:415-418.
15. Maslanka K., Yassai M., Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J Clin Invest 1996, 98:1802-1808.
16. Roberts I., Murray N.A. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed 2003, 88:F359-F364.
17. Espinoza J.P., Caradeux J., Norwitz E.R., Illanes S.E. Fetal and neonatal alloimmune thrombocytopenia. Rev Obstet Gynecol 2013, 6:e15-e21. 10.3909/riog0202.
18. Kiefel V., Konig C., Kroll H., Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001, 41:766-770.
19. Lucas G.F., Pittman S.J., Davies S., Solanki T., Bruggemann K. Post-transfusion purpura (PTP) associated with anti-HPA-1a, anti-HPA-2b and anti-HPA-3a antibodies. Transfus Med 1997, 7:295-299.
20. Wegner N., Lundberg K., Kinloch A., Fishor B., Malmstrom V., Feldmann M., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54.
21. van Venrooji W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008, 1143:268-285.
22. van Gaalen F.A., Linn-Rasker S.P., van Venrooji W.J., de Jong B.A., Breedveld F.C., Verweij C.L., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50:709-715.
23. Kudo-Tanaka E., Ohshima S., Ishii M., Mima T., Matsushita M., Azuma N., et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis (RA) in early undifferentiated arthritis. Clin Rheumatol 2007, 26:1627-1633.
24. Vossenaar E.R., Zendman A.J., van Verooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
25. Foulquier C., Sebbag M., Clavel C., Chapuy-Regaud S., Al Badine R., Mechin M.C., et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56:3541-3553.
26. Kinloch A., Lundberg K., Wait R., Wegner N., Lim N.H., Zendman A.J., et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008, 58:2287-2295.
27. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003, 34:395-402.
28. Snyderman R., McCarty G.A. Analogous mechanisms of tissue destruction in rheumatoid arthritis and periodontal disease. Host-parasite interaction in periodontal diseases 1982, 354-362. American Society of Microbiology, USA: Washington, DC. R.J. Genco, S.E. Mergenhagen (Eds.).
29. Holt S., Bramanti T.E. Factors in virulence expression and their role in periodontal disease pathogenesis. Crit Rev Oral Biol Med 1991, 2:177-281.
30. Haffajee A.D., Socransky S.S. Micro biological etiological agents of destructive periodontal diseases. Periodontology 1994, 5:78-111.
31. McGraw W.T., Potempa J., Farley D., Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun 1999, 67:3248-3256.
32. Rodriguez S.B., Stitt B.L., Ash D.E. Expression of peptidylarginine deiminase from Porphyromonas gingivalis in Escherichia coli: enzyme purification and characterization. Arch Biochem Biophys 2009, 488:14-22.
33. Mangat P., Wegner N., Venables P.J., Potempa J. Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis. Arthritis Res Ther 2010, 12:209. 10.1186/ar3000.
34. Wegner N., Wait R., Sroka A., Eick S., Nguyen K.A., Lundberg K., et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implication for autoimmune in rheumatoid arthritis. Arthritis Rheum 2010, 62:2662-2672.
35. Koller H., Kieseier B.C., Jander S., Hartung H.P. Chronic inflammatory demyelinating neuropathy. N Engl J Med 2005, 352:1343-1356.
36. Kieseier B.C., Wiendl H., Hartung H.P. The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006, 19:433-436.
37. Yuki N., Taki T., Inagaki F., Kasama T., Takahashi M., Saito K., et al. A bacterium lipopolysaccharide that elicits Guillan-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993, 178:1771-1775.
38. Yuki N., Okada M. Ganglioside mimicry as a cause of Guillan-Barre syndrome. Curr Opin Neurol 2005, 18:557-561.
39. Burke A.J., Chang C. Diagnostic criteria of acute rheumatic fever. Autoimmun Rev 2014, 13:503-507.
40. Nelson D.C., Garbe J., Collin M. Cysteine proteinase SpeB from Streptococcus pyogenes: a potent modifier of immunologically important host and bacterial proteins. Biol Chem 2011, 392:1077-1088.
41. Chiang-Ni C., Wu J.J. Effects of streptococcal pyrogenic exotoxin B on pathogenesis of Streptococcus pyogenes. J Formos Med Assoc 2008, 107:677-685.
42. Honda-Ogawa M., Ogawa T., Terao Y., Sumitomo T., Nakata M., Ikebe K., et al. Cysteine proteinase fromStreptococcus pyogenes enables evasion of innate immunity via degradation of complement factors. J Biol Chem 2013, 288:15854-15864.
43. von Pawel-Rammingen U., Johansson B.P., Bjorck L. Ides, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002, 21:1607-1615.
44. Collin M., Shannon O., Bjrck L. IgG glycan hydrolysis by bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A 2008, 105:4265-4270.
45. Allhorn M., Olin A.I., Mimmerjahn F., Collin M. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One 2008, 3:e1413.
46. McCulloch J., Zhang Y.W., Dawson M., Harkiss G.D., Peterhans E., Vogt H.R., et al. Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int 1995, 14:243-248.
47. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndrome. Cell 1999, 97:133-144.
48. Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2011, 167:391-404.
49. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory diseases. Annu Rev Immunol 2009, 27:621-668.
50. Park H., Bourla A.B., Kastner D.L., Colbert R.A., Siegel R.M. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 2012, 12:570-580.
51. Brydges S.D., Mueller J.L., McGeough M.D., Pena C.A., Misaghi A., Gandhi C., et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 2009, 30:875-887.
52. Atsumi T., Ishihara K., Kitamura D., Ikushima H., Ohtani T., Hirota S., et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002, 196:979-990.
53. Kawagoe T., Takeuchi O., Takabatake Y., Kato H., Isaka Y., Tsujimura T., et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 2009, 10:965-972.
54. Dixit V.M., Green S., Sarma V., Holzman L.B., Wolf F.W., O'Rourke K., et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage specific chemotaxin. J Biol Chem 1990, 265:2973-2978.
55. Opipari A.W., Boguski M.S., Dixit V.M. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990, 265:14705-14708.
56. Catrysse L., Vereecke L., Beyaert R., van Loo G. A20 in inflammation and autoimmunity. Trends Immunol 2014, 35:22-31.
57. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulation of immunopathology. Trends Immunol 2013, 30:383-391.
58. Ma A., Malynn B.A. A20: linking a complex regulator of ubiquitylation to immunity and human diseases. Nat Rev Immunol 2012, 12:774-785.
59. Niewold T.B., Clark D.N., Salloum R., Poole B.D. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010. [Epub 2010 Jun 29]. 10.1155/2010/948364.
60. Rigante D., Mazzoni M.B., Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev 2013, 12:726-740.
61. Sciascia S., Ceberio L., Garcia-Fernandez C., Roccarello D., Karim Y., Cuadrado M.J. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 2012, 12:157-163.
62. Calixto O.J., Franco J.S., Anaya J.M. Lupus mimickers. Autoimmun Rev 2014, 13:865-872.
63. Bogdanos D.P., Smyk D.S., Invernizzi P., Rigopoulou E.I., Blank M., Pouria S., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013, 12:726-740.